Quetiapine augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: Is response to treatment predictable?

International Clinical Psychopharmacology

Volumn 27, Issue 6, 2012, Pages 321-325

  Carey, Paul D ^a   Lochner, Christine ^a   Kidd, Martin ^a   Van Ameringen, Michael ^c,d   Stein, Dan J ^b   Denys, Damiaan ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c MCMASTER UNIVERSITY   (Canada)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

obsessive compulsive disorder; quetiapine augmentation; serotonin reuptake inhibitors

Indexed keywords

PLACEBO; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CHECKLIST; DRUG POTENTIATION; HUMAN; META ANALYSIS; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME; TREATMENT RESPONSE;

DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84867020748     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3283576881     Document Type: Article

References (42)

1. Ackerman DL, Greenland S, Bystritsky A, Morgenstern H, Katz RJ (1994). Predictors of treatment response in obsessive-compulsive disorder: multivariate analyses from a multicenter trial of clomipramine. J Clin Psychopharmacol 14:247-254. (Pubitemid 24254716)
2. Ackerman DL, Greenland S, Bystritsky A (1996). Use of receiver-operator characteristic (ROC) curve analysis to evaluate predictors of response to clomipramine therapy. Psychopharmacol Bull 32:157-165. (Pubitemid 26176217)
3. Ackerman DL, Greenland S, Bystritsky A (1998). Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 18:185-192. (Pubitemid 28266883)
4. Ackerman DL, Greenland S, Bystritsky A (1999). Side effects as predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol 19:459-465. (Pubitemid 29451511)
5. Alonso P, Menchon JM, Pifarre J, Mataix-Cols D, Torres L, Salgado P, Vallejo J (2001). Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. J Clin Psychiatry 62:535-540. (Pubitemid 32703093)
6. Baer L (1994). Factor analysis of symptom subtypes of obsessive-compulsive disorder and their relation to personality and tic disorders. J Clin Psychiatry 55 (Suppl):18-23. (Pubitemid 24113071)
7. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, Zohar J, et al. (2008). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World J Biol Psychiatry 9:248-312.
8. Black DW, Monahan P, Gable J, Blum N, Clancy G, Baker P (1998). Hoarding and treatment response in 38 nondepressed subjects with obsessive-compulsive disorder. J Clin Psychiatry 59:420-425. (Pubitemid 28391564)
9. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF (2006). A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11: 622-632. (Pubitemid 43989810)
10. Carey PD, Vythilingum B, Seedat S, Muller JE, Van Ameringen M, Stein DJ (2005). Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry 5:5.
11. Damecour CL, Charron M (1998). Hoarding: a symptom, not a syndrome. J Clin Psychiatry 59:267-272. (Pubitemid 28274617)
12. Denys D, Burger H, van Megen H, de Geus F,Westenberg H (2003). A score for predicting response to pharmacotherapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 18:315-322. (Pubitemid 38183484)
13. Denys D, de Geus F, van Megen HJ, Westenberg HG (2004). A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 65:1040-1048.
14. Denys D, Fineberg N, Carey PD, Stein DJ (2007a). Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biol Psychiatry 61:412-414. (Pubitemid 46108696)
15. Denys D, Van Nieuwerburgh F, Deforce D, Westenberg HG (2007b). Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry 68:747-753. (Pubitemid 46841858)
16. Drummond LM (1993). The treatment of severe, chronic, resistant obsessive-compulsive disorder. An evaluation of an in-patient programme using behavioural psychotherapy in combination with other treatments. Br J Psychiatry 163:223-229. (Pubitemid 23233092)
17. Eddy KT, Dutra L, Bradley R,Westen D (2004). A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 24:1011-1030. (Pubitemid 40247306)
18. Erzegovesi S, Cavallini MC, Cavedini P, Diaferia G, Locatelli M, Bellodi L (2001). Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol 21:488-492. (Pubitemid 32937431)
19. Fineberg NA, Gale TM (2005). Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol 8:107-129. (Pubitemid 40388819)
20. Fineberg NA, Sivakumaran T, Roberts A, Gale T (2005). Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol 20:223-226. (Pubitemid 40896377)
21. Fineberg NA, Stein DJ, Premkumar P, Carey P, Sivakumaran T, Vythilingum B, et al. (2006). Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials. Int Clin Psychopharmacol 21:337-343. (Pubitemid 44498275)
22. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS (1989a). The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 46:1012-1016. (Pubitemid 19278230)
23. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. (1989b). The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46:1006-1011. (Pubitemid 19278229)
24. Greist JH, Jefferson JW (1998). Pharmacotherapy for obsessive-compulsive disorder. Br J Psychiatry Suppl 35:64-70.
25. Guy W (1976). ECDEU assessment manual for psychopharmacology. Publication no. 76-338. Washington, DC: Superintendent of Documents, US Government Printing Office, US Department of Health, Education, and Welfare.
26. Ipser JC, Carey P, Dhansay Y, Fakier N, Seedat S, Stein DJ (2006). Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev 4:CD005473.
27. Karno M, Golding JM, Sorenson SB, Burnam MA (1988). The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 45:1094-1099. (Pubitemid 19005463)
28. Keuneman RJ, Pokos V, Weerasundera R, Castle DJ (2005). Antipsychotic treatment in obsessive-compulsive disorder: a literature review. Aust N Z J Psychiatry 39:336-343. (Pubitemid 40740305)
29. Leckman JF, Grice DE, Boardman J, Zhang H, Vitale A, Bondi C, et al. (1997). Symptoms of obsessive-compulsive disorder. Am J Psychiatry 154:911-917. (Pubitemid 27274532)
30. Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L (1999). Use of factoranalyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry 156:1409-1416. (Pubitemid 29416539)
31. McDougle CJ (1997). Update on pharmacologic management of OCD: agents and augmentation. J Clin Psychiatry 58 (Suppl 12):11-17. (Pubitemid 27516505)
32. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH (1994). Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 51:302-308. (Pubitemid 24127303)
33. Murray CJL, Lopez AD (1996). Global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Vol. 1: Harvard: World Health Organization.
34. Pigott TA (1998). Obsessive-compulsive disorder: symptom overview and epidemiology. Bull Menninger Clin 62 (Suppl A):A4-32. (Pubitemid 28509612)
35. Pigott TA, Seay SM (1999). A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 60:101-106. (Pubitemid 29104386)
36. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G (1995). Predictors of drug treatment response in obsessive-compulsive disorder. J Clin Psychiatry 56:368-373.
37. Roseboom PH, Kalin NH (2000). Neuropharmacology of venlafaxine. Depress Anxiety 12 (Suppl 1):20-29.
38. Shetti CN, Reddy YC, Kandavel T, Kashyap K, Singisetti S, Hiremath AS, et al. (2005). Clinical predictors of drug nonresponse in obsessive-compulsive disorder. J Clin Psychiatry 66:1517-1523. (Pubitemid 43068689)
39. Stassen H, Anghelescu IG, Angst J, Boker H, Lotscher K, Rujescu D, et al. (2011). Predicting response to psychopharmacological treatment: survey of recent results. Pharmacopsychiatry 44:263-272.
40. Stein DJ, Montgomery SA, Kasper S, Tanghoj P (2001). Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder. Int Clin Psychopharmacol 16:357-361. (Pubitemid 33030052)
41. Steketee G, Eisen J, Dyck I, Warshaw M, Rasmussen S (1999). Predictors of course in obsessive-compulsive disorder. Psychiatry Res 89:229-238.
42. Stern RS, Marks IM, Mawson D, Luscombe DK (1980). Clomipramine and exposure for compulsive rituals: II. Plasma levels, side effects and outcome. Br J Psychiatry 136:161-166. (Pubitemid 10183251)